Empaveli is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. The FDA requires REMS programs for some medicines that have serious safety concerns.

Learn about cost and Empaveli, financial and insurance assistance, ways to lower long-term costs, and more.

Get the facts on cost and Empaveli, how generics compare with brand names, what financial assistance may be available, and more.

The top line lost 3% year over year as sales of Syfovre (pegcetacoplan injection) were impacted by inventory and funding shortage at co-pay assistance programs in the reported quarter. Syfovre was ...

Underfunding of copay assistance programs—which Regeneron’s CEO also lamented on his company’s earnings call last month—has forced Apellis to give away more Syfovre samples.

Empaveli is a prescription drug used to treat paroxysmal nocturnal hemoglobinuria. Learn about side effects of the drug and how to manage them.

Empaveli, which is used to treat a rare blood disorder, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a complement inhibitor indicated to treat adult patients with PNH. The report ...

Reports Q1 revenue $166.8M, consensus $194.88M. “In the first quarter, we were pleased to see continued growth in SYFOVRE injection demand-a key in ...

Apellis Pharmaceuticals Inc (APLS) reports robust market share growth for SYFOVRE despite revenue shortfalls and co-pay assistance hurdles.

“We have continued to execute well and progress our programs over the past six months. SYFOVRE delivered strong growth and is reaching more people living with geographic atrophy, EMPAVELI ...

EMPAVELI REMS EMPAVELI is available only through a restricted program under a REMS called EMPAVELI REMS, because of the risk of serious infections caused by encapsulated bacteria.